Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Freedom Finance and Binance Join Forces in Digital Assets 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Meta Platforms Cuts Equity Awards Again Amid Massive AI Investment Push 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Nvidia Nears $30 Billion Investment in OpenAI, Replacing Previous $100 Billion AI Partnership 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
BUENA, N.J., May 07, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Deutsche Bank’s 43rd Annual Health Care Conference. The Conference is taking place May 8-9, 2018 at the Intercontinental Hotel, Boston.
Damian Finio, Chief Financial Officer of Teligent, Inc., will present on Tuesday, May 8th at 2:10 p.m. ET.
The presentation will be webcast and accessible online via the investors section of the Company's website at www.teligent.com. A replay will be available for 30 days.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com
